Jechobio JL19001 Injection Approved for Second Indication to Advance Treatment of Advanced Tumors and Lymphoma

Recently, JL19001 Injection, an innovative drug independently developed by Jecho (Tianjin) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jecho bio"), has been officially granted the Clinical Trial Approval Notice by the National Medical Products Administration (NMPA). The newly approved indications cover advanced solid tumors (AST) and relapsed or refractory B-cell non-Hodgkin's lymphoma (r/r B-NHL). This marks the second investigational new drug (IND) approval for the JL19001 program for a new indication, laying a solid foundation for the company’s commercial cooperation in the field of tumor immunology. As a Class I innovative drug prioritized in Jechbio’s R&D pipeline, JL19001 Injection is a fusion protein composed of recombinant human serum albumin (HSA) and IL-15Rα/IL-15. It specifically activates natural killer (NK) cells and CD8+ T cells, thereby enhancing both innate and adaptive immune responses. With its unique mechanism of action and remarkable therapeutic potential, IL-15 has emerged as a high-profile "rising star" in the field of cancer immunotherapy. The JL19001 program has achieved multiple phased breakthroughs prior to this approval. In September 2025, the product obtained NMPA clinical trial approval to launch clinical research targeting non-muscle invasive bladder cancer, which was the first IND approval for the JL19001 program. In addition, in November 2025, the product successfully received clinical trial authorization from the U.S. Food and Drug Administration (FDA) for the same indication of non-muscle invasive bladder cancer, marking a critical step forward in the global development of JL19001. The approval of the new indications expands the product’s application scenarios and opens up broader space for project cooperation. Going forward, Jechobio will accelerate the progress of clinical trials, pursue diversified cooperation based on the product’s strengths, and work with partners to drive the development of the tumor immunotherapy industry.

The release as fetched from its publisher. jechobio.com ↗